Equity Offering

January 16, 2020

Biopharma venture financing retreats, but not by much

Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.

September 05, 2019

Esmo 2019 preview – Parps on parade

Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.

June 19, 2019

G1 makes the most of trilaciclib's unclear survival benefit

G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.

August 13, 2018

Data point - Orchard growth

July 09, 2018

The venture money keeps flowing for biopharma

Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.

May 18, 2018

Snippet roundup: One in, one out in Alzheimer's, but for Lilly oncology is bigger

May 11, 2018

Snippet roundup: Pivotal fluffs from Faron and Fasenra

May 04, 2018

Snippet roundup: The good times roll for Moderna, but Mallinckrodt and Smith & Nephew flag

March 23, 2018

Snippet roundup: Funding boosts the US NIH and could spawn a UK ubercorn

March 21, 2018

Proteostasis’s credibility slowly unwinds

March 16, 2018

Ionis gives a lesson in financial engineering

Load More